Please use this identifier to cite or link to this item: http://sgc.anlis.gov.ar/handle/123456789/1317
Title: Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial
Authors: Villar, Juan Carlos 
Herrera, Víctor Mauricio 
Pérez Carreño, Juan Guillermo 
Váquiro Herrera, Eliana 
Castellanos Domínguez, Yeny Zulay 
Vásquez, Skarlet Marcell 
Cucunubá, Zulma Milena 
Prado, Nilda Graciela 
Hernández, Yolanda 
Keywords: Ensayos Clínicos Controlados Aleatorios como Asunto;Nifurtimox;Trypanosoma cruzi
Issue Date: 15-Jul-2019
Journal: Trials 
Abstract: 
Either benznidazole (BZN) or nifurtimox (NFX) is recommended as equivalent to treat Trypanosoma cruzi infection. Nonetheless, supportive data from randomised trials is limited to individuals treated with BZN in southern cone countries of Latin America.
URI: http://sgc.anlis.gob.ar/handle/123456789/1317
DOI: 10.1186/s13063-019-3423-3
Appears in Collections:Publicaciones INP

Show full item record

Page view(s)

4
checked on Jul 4, 2020

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.